1
|
Pre-clinical drug-drug interactions (DDIs) of gefitinib with/without losartan and selective serotonin reuptake inhibitors (SSRIs): citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, and venlafaxine. CURRENT RESEARCH IN PHARMACOLOGY AND DRUG DISCOVERY 2022; 3:100112. [PMID: 35756846 PMCID: PMC9218239 DOI: 10.1016/j.crphar.2022.100112] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2022] [Revised: 05/23/2022] [Accepted: 06/06/2022] [Indexed: 11/23/2022] Open
Abstract
Objective Methods Results Conclusion In vitro hepatocytes assays can predict relevant drug-drug interactions (DDIs). Proof-of concept data testing can provide a clear insight of multidrug regimen DDIs. Classifying drugs as inhibitors/inducers alone cannot successfully identify DDIs. Regimens requiring three or more drugs may cause significant DDIs (p-value < 0.05). SSRI metabolism by human hepatocytes can be affected by gefitinib and losartan.
Collapse
|
2
|
Hosomi Y, Tanai C, Yoh K, Goto Y, Sakai H, Kato T, Kaburagi T, Nishio M, Kim YH, Inoue A, Hasegawa Y, Isobe H, Tomizawa Y, Mori Y, Minato K, Yamada K, Ohashi Y, Kunitoh H. Characteristics and outcomes of patients with EGFR-mutation positive non-small-cell lung cancer receiving gefitinib beyond radiological progression. Expert Opin Pharmacother 2018; 19:1049-1056. [PMID: 29871540 DOI: 10.1080/14656566.2018.1484903] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
Abstract
BACKGROUND This study aimed to analyze the characteristics and outcomes of patients suffering from non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor mutations (EGFRm+) receiving gefitinib who remained clinically stable following confirmation of progressive disease (PD) using Response Evaluation Criteria in Solid Tumors (RECIST) (R-PD) and identify those who benefited from tyrosine kinase inhibitor therapy beyond PD. RESEARCH DESIGN AND METHODS The clinical courses of patients with EGFRm+ advanced NSCLC who received first-line gefitinib were investigated. Clinical PD (C-PD) was defined as one or more of the following: (1) symptomatic PD, (2) worsening performance status resulting from PD, (3) threat to a major organ(s), or (4) unequivocal multiorgan PD. RESULTS Of 529 patients, 258 experienced R-PD without C-PD. Among 258 patients, 91 received gefitinib beyond R-PD. Females were more likely to receive gefitinib beyond R-PD and exhibit a longer time from R-PD to C-PD than males (median days, 175 vs. 79.5). Survival beyond R-PD tended to be longer for elderly patients who received gefitinib beyond PD than for those who did not (median days, 458 vs. 336), but this was not the case for non-elderly patients (median days, 481 vs. 487). CONCLUSIONS Some patients may benefit from continuation of gefitinib beyond PD.
Collapse
Affiliation(s)
- Yukio Hosomi
- a Department of Thoracic Oncology and Respiratory Medicine , Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital , Tokyo , Japan
| | - Chiharu Tanai
- b Division of Respirology , NTT Medical Center Tokyo , Tokyo , Japan
| | - Kiyotaka Yoh
- c Department of Thoracic Oncology , National Cancer Center Hospital East , Kashiwa , Japan
| | - Yasushi Goto
- d Department of Thoracic Oncology , National Cancer Center Hospital , Tokyo , Japan
| | - Hiroshi Sakai
- e Department of Thoracic Oncology , Saitama Cancer Center , Saitama , Japan
| | - Terufumi Kato
- f Department of Respiratory Medicine , Kanagawa Cancer Center , Yokohama , Japan
| | - Takayuki Kaburagi
- g Division of Respiratory Medicine , Ibaraki Prefectural Central Hospital , Kasama , Japan
| | - Makoto Nishio
- h Department of Thoracic Medical Oncology , The Cancer Institute Hospital of the Japanese Foundation for Cancer Research , Tokyo , Japan
| | - Young Hak Kim
- i Department of Respiratory Medicine , Graduate School of Medicine, Kyoto University , Kyoto , Japan
| | - Akira Inoue
- j Department of Palliative Medicine , Tohoku University School of Medicine , Aoba-ku Sendai , Japan
| | - Yoshinori Hasegawa
- k Department of Respiratory Medicine , Nagoya University Graduate School of Medicine , Nagoya , Japan
| | - Hiroshi Isobe
- l Department of Medical Oncology , KKR Sapporo Medical Center , Sapporo , Japan
| | - Yoshio Tomizawa
- m Department of Respiratory Medicine , National Hospital Organization Shibukawa Medical Center , Shibukawa , Japan
| | - Yoshiaki Mori
- n Department of Respiratory Medicine , Iwate Prefectural Central Hospital , Morioka , Japan
| | - Koichi Minato
- o Department of Respiratory Medicine , Gunma Prefectural Cancer Center , Ota , Japan
| | - Kazuhiko Yamada
- p Department of Internal Medicine , Kurume University School of Medicine , Kurume , Japan
| | - Yasuo Ohashi
- q Department Integrated Science and Engineering for Sustainable Society , Chuo University , Tokyo , Japan
| | - Hideo Kunitoh
- r Department of Medical Oncology , Japanese Red Cross Medical Center , Tokyo , Japan
| |
Collapse
|